Table 1.
Baseline characteristics for the ITT population.
| Tasimelteon | Placebo | Total | |
|---|---|---|---|
| 20 mg (N = 159) | (N = 159) | (N = 318) | |
| Age (year) | 35.8 (11.20) | 35.9 (12.63) | 35.8 (11.92) |
| Sex | |||
| Male | 73 (45.9%) | 78 (49.1%) | 151 (47.5%) |
| Female | 86 (54.1%) | 81 (50.9%) | 167 (52.5%) |
| Baseline BMI (kg/m2) | 25.1 (3.04) | 24.8 (3.00) | 25.0 (3.02) |
| Baseline MEQ | 59.0 (7.78) | 58.4 (8.52) | 58.7 (8.16) |
| Race | |||
| White | 94 (59.1%) | 97 (61.0%) | 191 (60.1%) |
| Black or African American | 44 (27.7%) | 47 (29.6%) | 91 (28.6%) |
| Asian | 15 (9.4%) | 13 (8.2%) | 28 (8.8%) |
| Native Hawaiian or Other Pacific Islander | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| American Indian or Alaska Native | 1 (0.6%) | 0 (0.0%) | 1 (0.3%) |
| Other | 5 (3.1%) | 2 (1.3%) | 7 (2.2%) |
Data are n (%), or mean (SD). Baseline is defined as the last non-missing measurement prior to start of study drug.
BMI, Body Mass Index; MEQ, Morningness-Eveningness Questionnaire.